November 5, 2002

FOR: ZOLL Medical Corporation

INVESTOR CONTACT: A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832
rminicucci@zoll.com



FOR IMMEDIATE RELEASE

ZOLL M Series CCT Selected as the Defibrillator for the Military Patient Movement Item Program

BURLINGTON, MA  Tuesday, November 05, 2002 – ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices, today announced that it has been awarded a sole source contract to standardize transport defibrillators for the United States Military. The $8.9 million award is an integral part of the military's Patient Movement Item (PMI) program. ZOLL’s M Series CCT biphasic transport defibrillator was chosen by the tri-service technical evaluation and selection committee. Initial use will be by the Critical Care Aeromedical Transport Teams (CCATT). Selection of this single defibrillator platform will allow PMI to standardize equipment across all branches of the military for transport of critically injured personnel.

Designed specifically for patient transport, the M Series CCT represents a significant extension of the highly successful M Series platform. Its large color display, extended battery life, and integrated power supply optimize it for critical transports both outside and within the hospital. The PMI taskforce selected fully featured CCT units that incorporate external pacing, Masimo pulse oximetry, mainstream capnography, interpretive 12 lead ECG, invasive and noninvasive blood pressure, and temperature.

Richard A. Packer, President and Chief Executive Officer of ZOLL stated, “This order represents the single largest order in ZOLL’s history. Last year, the United States Navy standardized its entire naval fleet on the ZOLL M Series platform. We are extremely pleased to expand further our successful relationship with the U. S. Military. These orders reflect the value that our customers perceive, when it comes to saving lives, from standardizing on our products.”

Mr. Packer added, “The M Series CCT biphasic transport defibrillator chosen by the PMI program provides the United States Military with the smallest, lightest, fully featured defibrillator on the market. In addition, it provides the only clinically superior, low-energy biphasic waveform on the market.”

Mr. Packer concluded, “We are thrilled to have the opportunity to play an important role in protecting our troops around the globe and look forward to initial shipments under this contract in the second quarter of 2003.”

ZOLL Medical Corporation, headquartered in Burlington, MA, designs, manufactures and markets an integrated line of proprietary, non-invasive resuscitation devices and disposable electrodes. Used by health care professionals to provide both types of cardiac resuscitation—pacing and defibrillation—these products are essential in the emergency treatment of cardiac arrest victims, both inside and outside the hospital. ZOLL also designs and markets software that automates collection and management of both clinical and non-clinical data for emergency medical service providers. ZOLL has operations in the United States, Canada, United Kingdom, Germany, France, the Netherlands and Australia, and business partners in all of the world’s major markets. For more information about ZOLL and its products, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the anticipated development of ZOLL’s business, the intent, belief or current expectations of ZOLL, its directors or its officers, primarily with respect to ZOLL’s business model and future operating performance of ZOLL, including expectations regarding results in future periods, operating performance and contributions to results from ZOLL’s new Public Access Defibrillation product, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the ZOLL’s Annual Report on Form 10-Q filed on August 14, 2002, the future performance of the direct sales operations, the outcome of a pending patent infringement suit relating to the ZOLL AED Plus, as well as uncertainties regarding the market, acceptance and profitability of the ZOLL AED Plus and M Series CCT, the length and severity of the current economic slowdown and its impact on capital spending budgets, the reduction in overall capital equipment expenditures in the hospital and pre-hospital markets, the potential disruption in the transportation industry on ZOLL’s supply chain and product distribution channels, and the desire or ability of other parties to purchase the ZOLL’s products.

# # #